These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Metastatic pancreatic adenocarcinoma: current standards, future directions. Duffy A; Kummar S Am J Ther; 2010; 17(1):79-85. PubMed ID: 19636248 [TBL] [Abstract][Full Text] [Related]
7. What treatment in 2017 for inoperable pancreatic cancers? Taieb J; Pointet AL; Van Laethem JL; Laquente B; Pernot S; Lordick F; Reni M Ann Oncol; 2017 Jul; 28(7):1473-1483. PubMed ID: 28459988 [TBL] [Abstract][Full Text] [Related]
8. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269 [TBL] [Abstract][Full Text] [Related]
9. [Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer]. Ryu JK Korean J Gastroenterol; 2015 Sep; 66(3):150-3. PubMed ID: 26387697 [TBL] [Abstract][Full Text] [Related]
10. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017. Cinar P; Ko AH Chin Clin Oncol; 2017 Jun; 6(3):29. PubMed ID: 28705006 [TBL] [Abstract][Full Text] [Related]
11. Currently available first-line drug therapies for treating pancreatic cancer. Olson JL; Bold RJ Expert Opin Pharmacother; 2018 Dec; 19(17):1927-1940. PubMed ID: 30325679 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic advances in metastatic pancreatic adenocarcinoma and related cancers: focus on evidence-based and sequenced approaches to survival extension in metastatic pancreatic adenocarcinoma. Bekaii-Saab T; Yu K; Lima CMSR; Wolin EM Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):1-16. PubMed ID: 30807558 [No Abstract] [Full Text] [Related]
13. Treatment of metastatic pancreatic adenocarcinoma: a review. Thota R; Pauff JM; Berlin JD Oncology (Williston Park); 2014 Jan; 28(1):70-4. PubMed ID: 24683721 [TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Ruess DA; Görgülü K; Wörmann SM; Algül H Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415 [TBL] [Abstract][Full Text] [Related]
15. Advanced pancreatic cancer - how to choose an adequate treatment option. Korkeila EA World J Gastroenterol; 2015 Oct; 21(38):10709-13. PubMed ID: 26478662 [TBL] [Abstract][Full Text] [Related]
16. Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study. Smyth EN; Bapat B; Ball DE; André T; Kaye JA Clin Ther; 2015 Jun; 37(6):1301-16. PubMed ID: 25907619 [TBL] [Abstract][Full Text] [Related]
17. Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study. Kunzmann V; Ramanathan RK; Goldstein D; Liu H; Ferrara S; Lu B; Renschler MF; Von Hoff DD Pancreas; 2017 Feb; 46(2):203-208. PubMed ID: 27841795 [TBL] [Abstract][Full Text] [Related]
18. Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report. Zhao J; Shen H; Hu HG; Huang JJ World J Gastroenterol; 2015 Mar; 21(11):3441-6. PubMed ID: 25805958 [TBL] [Abstract][Full Text] [Related]
19. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer. Ur Rehman SS; Lim K; Wang-Gillam A Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737 [TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]